Isabelle Navarro-Teulon

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice
    Maha Z Ladjemi
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Inserm U896, Université Montpellier1, CRLC Val d Aurelle Paul Lamarque, 208 Rue des Apothicaires, Montpellier, F 34298, France
    Breast Cancer Res 13:R17. 2011
  2. pmc Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies
    Vincent Boudousq
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
    J Nucl Med 51:1748-55. 2010
  3. pmc Anti-HER2 vaccines: new prospects for breast cancer therapy
    Maha Zohra Ladjemi
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Inserm U896, Université Montpellier1, Montpellier, France
    Cancer Immunol Immunother 59:1295-312. 2010
  4. pmc Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis
    Lore Santoro
    Institut de Recherche en Cancérologie de Montpellier, INSERM, U896, Montpellier, France
    J Nucl Med 50:2033-41. 2009
  5. pmc Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein
    Claire Germain
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Inserm U896, Université Montpellier1, Montpellier F 34298, France
    Protein Eng Des Sel 21:665-72. 2008
  6. doi request reprint The lipid-modulating effects of a CD4-specific recombinant antibody correlate with ZAP-70 segregation outside membrane rafts
    Myriam Chentouf
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier F 34298, France
    Immunol Lett 133:62-9. 2010
  7. doi request reprint A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy
    Nidia Alvarez-Rueda
    IRCM Institut de Recherche en Cancérologie de Montpellier, Inserm U896, Universite Montpellier 1, CRLC Val d Aurelle Paul Lamarque, Montpellier Cedex 5, France
    Vaccine 27:4826-33. 2009

Collaborators

  • Jean Pierre Pouget
  • William Jacot
  • Sebastien Mongrand
  • Francois Quenet
  • Andre Pelegrin
  • Caroline Bascoul-Mollevi
  • Thierry Chardes
  • Veronique Garambois
  • Maha Zohra Ladjemi
  • Vincent Boudousq
  • Maha Z Ladjemi
  • Myriam Chentouf
  • Stéphanie Corgnac
  • Bruno Robert
  • Sébastien Morisseau
  • Samir Boutaleb
  • Pierre Olivier Kotzki
  • Nidia Alvarez-Rueda
  • Lore Santoro
  • Claire Germain
  • Imade Ait Arsa
  • Soufiane Ghannam
  • Manuel Bardies
  • Pierre Emmanuel Colombo
  • Stéphanie Ricaud
  • Maxime Rigo
  • Muriel Busson
  • Martine Pugniere
  • Francoise Roquet
  • Monique Pèlegrin
  • Daniel Baty
  • Ghislaine Behar
  • Jean Pierre Mach
  • Imed Salhi
  • Emmanuelle Campigna

Detail Information

Publications7

  1. pmc Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice
    Maha Z Ladjemi
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Inserm U896, Université Montpellier1, CRLC Val d Aurelle Paul Lamarque, 208 Rue des Apothicaires, Montpellier, F 34298, France
    Breast Cancer Res 13:R17. 2011
    ....
  2. pmc Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies
    Vincent Boudousq
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
    J Nucl Med 51:1748-55. 2010
    ..We assessed the efficiency and toxicity of brief intraperitoneal radioimmunotherapy using high activities of (125)I-labeled monoclonal antibody (mAb) in the treatment of small-volume peritoneal carcinomatosis...
  3. pmc Anti-HER2 vaccines: new prospects for breast cancer therapy
    Maha Zohra Ladjemi
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Inserm U896, Université Montpellier1, Montpellier, France
    Cancer Immunol Immunother 59:1295-312. 2010
    ..It can be delivered by dendritic cells or in a DNA, peptidic or proteic form. Another area of research concerns the use of anti-idiotypic antibodies mimicking HER2...
  4. pmc Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis
    Lore Santoro
    Institut de Recherche en Cancérologie de Montpellier, INSERM, U896, Montpellier, France
    J Nucl Med 50:2033-41. 2009
    ..Here, we assessed the in vivo biologic efficiency of internalizing and noninternalizing (125)I-labeled mAbs for the treatment of small solid tumors...
  5. pmc Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein
    Claire Germain
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Inserm U896, Université Montpellier1, Montpellier F 34298, France
    Protein Eng Des Sel 21:665-72. 2008
    ....
  6. doi request reprint The lipid-modulating effects of a CD4-specific recombinant antibody correlate with ZAP-70 segregation outside membrane rafts
    Myriam Chentouf
    IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier F 34298, France
    Immunol Lett 133:62-9. 2010
    ..2-induced activation of the acid sphingomyelinase/ceramide pathway is an important event for structuring raft platforms and transducing CD4-related intracellular signals, which can further fine-tune antibody-triggered tumoral effects...
  7. doi request reprint A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy
    Nidia Alvarez-Rueda
    IRCM Institut de Recherche en Cancérologie de Montpellier, Inserm U896, Universite Montpellier 1, CRLC Val d Aurelle Paul Lamarque, Montpellier Cedex 5, France
    Vaccine 27:4826-33. 2009
    ..These results indicate that sdAb 1HE could be used as an anti-idiotype-based vaccine to boost immunity in patients bearing HER2-positive tumours...